Drugs & Therapy Perspectives

, Volume 34, Issue 5, pp 216–221 | Cite as

Tailor the pharmacological management of childhood dystonia to meet the needs of each child

  • Adis Medical Writers
Disease Management


The diagnostic evaluation and treatment of childhood dystonia is complicated by the clinical and aetiological heterogeneity of the disorder, as well as by a shortage of adequate clinical trials. Clinical diagnosis is based on history and distinctive examination findings, which direct the assessment process. Treatment for childhood dystonia is mainly symptomatic, with therapy being customized based on the clinical situation of each child. Levodopa can aid in the diagnostic process, as well as being potentially therapeutic; when the cause of the dystonia is unknown, the use of levodopa should be initially considered. Other pharmacological options include trihexyphenidyl, baclofen, benzodiazepines, tetrabenazine and botulinum toxin. Drugs should be initiated at low doses and gradually increased as required for symptomatic improvement.


Compliance with ethical standards

Conflict of interest

The article was adapted from Pediatric Drugs 2017;19(5):447–61 [3] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.


The preparation of this review was not supported by any external funding.


  1. 1.
    Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863–73.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Albanese A, Lalli S. Is this dystonia? Mov Disord. 2009;24(12):1725–31.CrossRefPubMedGoogle Scholar
  3. 3.
    Luc QN, Querubin J. Clinical management of dystonia in childhood. Pediatr Drugs. 2017;19(5):447–61.CrossRefGoogle Scholar
  4. 4.
    Mink JW. Special concerns in defining, studying, and treating dystonia in children. Mov Disord. 2013;28(7):921–5.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Jankovic J. Medical treatment of dystonia. Mov Disord. 2013;28(7):1001–12.CrossRefPubMedGoogle Scholar
  6. 6.
    van Egmond ME, Lugtenberg CHA, Brouwer OF, et al. A post hoc study on gene panel analysis for the diagnosis of dystonia. Mov Disord. 2017;32(4):569–75.CrossRefPubMedGoogle Scholar
  7. 7.
    Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5(10):864–72.CrossRefPubMedGoogle Scholar
  8. 8.
    Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66(1):11–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Liow NYK, Gimeno H, Lumsden DE, et al. Gabapentin can significantly improve dystonia severity and quality of life in children. Eur J Paediatr Neurol. 2016;20(1):100–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Sayer C, Lumsden DE, Kaminska M, et al. Clonidine use in the outpatient management of severe secondary dystonia. Eur J Paediatr Neurol. 2017;21(4):621–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Balash Y, Giladi N. Efficacy of pharmacological management of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol. 2004;11(6):361–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Grassi E, Latorraca S, Piacentini S, et al. Risperidone in idiopathic and symptomatic dystonia: preliminary experience. Neurol Sci. 2000;21(2):121–3.CrossRefPubMedGoogle Scholar
  13. 13.
    Miyazaki Y, Sako W, Asanuma K, et al. Efficacy of zolpidem for dystonia: a study among different subtypes. Front Neurol. 2012;3:58. Scholar
  14. 14.
    Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm. 1997;54:2461–77.PubMedGoogle Scholar
  15. 15.
    Koy A, Lin JP, Sanger TD, et al. Advances in management of movement disorders in children. Lancet Neurol. 2016;15(7):719–35.CrossRefPubMedGoogle Scholar
  16. 16.
    Bernard G, Vannase M, Chouinard S. A case of secondary dystonia responding to levodopa. J Child Neurol. 2010;25(6):780–1.CrossRefPubMedGoogle Scholar
  17. 17.
    Pozin I, Bdolah-Abram T, Ben-Pazi H. Levodopa does not improve function in individuals with dystonic cerebral palsy. J Child Neurol. 2013;29(4):534–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Hwang WJ, Calne DB, Tsui JKC, et al. The long-term response to levodopa in dopa-responsive dystonia. Parkinsonism Relat Disord. 2001;8(1):1–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology. 1986;36(2):160–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Fahn S. High dosage anticholinergic therapy in dystonia. Neurology. 1983;33(10):1255–61.CrossRefPubMedGoogle Scholar
  21. 21.
    Sanger TD, Bastian A, Brunstrom J, et al. Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy. J Child Neurol. 2007;22(5):530–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Rice J, Waugh MC. Pilot study on trihexyphenidyl in the treatment of dystonia in children with cerebral palsy. J Child Neurol. 2009;24(2):176–82.CrossRefPubMedGoogle Scholar
  23. 23.
    Ben-Pazi H. Trihexyphenidyl improves motor function in children with dystonic cerebral palsy: a retrospective analysis. J Child Neurol. 2011;26(7):810–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Hoon AHJ, Freese PO, Reinhardt. Age-dependent effects of trihexyphenidyl in extrapyramidal cerebral palsy. Pediatr Neurol. 2001;25(1):55–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Carranza-del Rio J, Clegg NJ, Moore A, et al. Use of trihexyphenidyl in children with cerebral palsy. Pediatr Neurol. 2011;44(3):202–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Greene PE, Fahn S. Baclofen in the treatment of idiopathic dystonia in children. Mov Disord. 1992;7(1):48–52.CrossRefPubMedGoogle Scholar
  27. 27.
    Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord. 1988;3(1):46–60.CrossRefPubMedGoogle Scholar
  28. 28.
    Lumsden DE, Kaminska M, Tomlin S, et al. Medication use in childhood dystonia. Eur J Paediatr Neurol. 2016;20(4):625–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Motta F, Stignani C, Antonello CE. Effect of intrathecal baclofen on dystonia in children with cerebral palsy and the use of functional scales. J Pediatr Orthop. 2008;28(2):213–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Albright AL, Barry MJ, Shafton DH, et al. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol. 2001;43(10):652–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Motta F, Antonello CE. Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. J Neurosurg Pediatr. 2014;13(3):301–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Chuang C, Fahn S, Frucht SJ. The natural history and treatment of acquired hemidystonia: report of 33 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2002;72(1):59–67.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Ghosh D, Indulkar S. Primary myoclonus-dystonia: a diagnosis often missed in children. J Child Neurol. 2013;28(11):1418–22.CrossRefPubMedGoogle Scholar
  34. 34.
    Jain S, Greene PE, Frucht SJ. Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Mov Disord. 2006;21(11):1966–72.CrossRefPubMedGoogle Scholar
  35. 35.
    Swash M, Roberts AH, Zakko H, et al. Treatment of involuntary movement disorders with tetrabenazine. J Neurol Neurosurg Psychiatry. 1972;35(2):186–91.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48(2):358–62.CrossRefPubMedGoogle Scholar
  37. 37.
    Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982;11(1):41–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Seiff SR, Freeman LN, Bluestone DL, et al. Use of botulinum toxin to treat blepharospasm in a 16-year-old with a dystonic syndrome. Pediatr Neurol. 1989;5(2):121–3.CrossRefPubMedGoogle Scholar
  39. 39.
    Heinen F, Korinthenberg R, Stücker R, et al. Dystonic posture of lower extremities associated with myelomeningocele: successful treatment with botulinum A toxin in a six-month-old child. Neuropediatrics. 1995;26(4):214–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Castelão M, Marques RE, Duarte GS, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2017;12:CD003633.PubMedGoogle Scholar
  41. 41.
    Marques RE, Duarte GS, Rodrigues FB, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2016;13(5):CD004315.Google Scholar
  42. 42.
    Brans JWM. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 1996;46(4):1066–72.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations